LENZ Therapeutics Inc (LENZ NASDAQ) stock market data APIs
$34.4708
0.2(0.6%)
as of July 10, 2025
Try our APIs with
free plan!
LENZ Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
LENZ Therapeutics, Inc. operates as a biopharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California.
Prev. Close
34.4708
Open
34.6687
High
35.7152
Low
32.4649
52 wk Range
16.535-38.93
Market Cap
980 M
P/E Ratio
52.7576
Shares Outstanding
28 146 K
EPS
-0.53
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get LENZ Therapeutics Inc data using free add-ons & libraries
Get LENZ Therapeutics Inc Fundamental Data
LENZ Therapeutics Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -59 364 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-07
- EPS/Forecast: -0.47
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
LENZ Therapeutics Inc News
New
Lenz Therapeutics stock gains as William Blair reiterates Outperform
Investing.com - Lenz Therapeutics Inc (NASDAQ:LENZ) stock gained after William Blair reiterated its Outperform rating on the presbyopia treatment developer. The stock has shown strong momentum, rising...
Warner Bros., Cidara, LENZ Therapeutics, and More Stocks See Action From Activist Investors
RA Capital raised its stake in biotech Cidara, Versant Venture lowered its stake in LENZ, Gamco reduced its stake in Oil-Dri, and more activist actions. Continue Reading View Comments
Versant sells LENZ therapeutics (LENZ) stock worth $10.1 million
Versant Venture Capital entities reported selling shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ), for a total of $10.1 million. The sales occurred at prices ranging from $29.95 to $30.35, near the cu...
LENZ Therapeutics and Lotus Pharmaceutical Announce Exclusive License and Commercialization Agreement for LNZ100 in the Republic of Korea and Southeast Asia
SAN DIEGO and TAIPEI, Taiwan, May 09, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ) and Lotus Pharmaceutical Co., Ltd. (“Lotus”, TWSW Stock Code: 1795) today announced an exclu...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
